Christophe Nicot, Kansas University Medical Center, USA
Call for papers
Advances in Nanomedicine for Cancer Therapy
Molecular Cancer invites submissions to this article collection. This Collection aims to explore innovative research and breakthrough developments in the application of nanotechnology for cancer diagnosis, treatment, and management. The collection is open to submissions till 30 June 2025.
Editor-in-Chief
Aims and scope
Molecular Cancer is an open access, peer-reviewed journal interested in attracting high-quality original research and reviews that present or highlight significant advances in all areas of cancer and related biomedical science.
Articles
-
-
Death-ision: the link between cellular resilience and cancer resistance to treatments
-
Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring
-
Dissecting small cell carcinoma of the esophagus ecosystem by single-cell transcriptomic analysis
-
Profiling triple-negative breast cancer-specific super-enhancers identifies high-risk mesenchymal development subtype and BETi-Targetable vulnerabilities
-
Thymoquinone attenuates tumor growth in ApcMin mice by interference with Wnt-signaling
-
mRNA vaccine for cancer immunotherapy
-
Mechanisms of receptor tyrosine kinase activation in cancer
-
Targeting PI3K in cancer: mechanisms and advances in clinical trials
-
The complexity of NF-κB signaling in inflammation and cancer
2024
Advances in Nanomedicine for Cancer Therapy
Edited by Christophe Nicot, Editor-in-Chief
2023
Aging and Cellular Fate: Senescence, Death, or Cancer
Edited by Christophe Nicot, Editor-in-ChiefLatest Correspondence on Biomarkers for Cancer diagnosis, prognosis, and drug resistance
Edited by Christophe Nicot, Editor-in-Chief
Phase 2 and 3 studies
Edited by Christophe Nicot, Editor-in-Chief
2022
Molecular understanding and clinical aspects of immunotherapy in the treatment of cancer
Edited by Christophe Nicot, Editor-in-Chief
Liquid Biopsy at the Frontier of Early Detection, Prognosis and Cancer Treatments
Edited by Christophe Nicot, Editor-in-Chief
Genome Editing and the Future of Personalized and Targeted Cancer Medicine
Edited by Christophe Nicot, Editor-in-Chief
2021
mRNA therapies and mRNA vaccines in cancer
Edited by Christophe Nicot, Editor-in-Chief
2020
Non-coding RNAs and RNA modifiers in cancer progression and cancer cells resistance to therapies
Edited by Christophe Nicot, Editor-in-Chief
2019
Microvesicles and Tumor Microenvironment in Cancer Development and Resistance to Therapies
Edited by Christophe Nicot, Editor-in-Chief
2018
Oncogenic Signaling of Tyrosine Kinase in Cancer: Challenges and Therapeutic Opportunities
Edited by Christophe Nicot, Editor-in-Chief
2017
Cancer Stem Cells
Edited by Christophe Nicot, Editor-in-Chief
2016
miRNA regulation in cancer
Edited by Christophe Nicot, Editor-in-Chief
Colorectal Cancer Awareness Month
In recognition of Colorectal Cancer Awareness Month this March, we have selected a collection of articles on colorectal cancer from across our open access portfolio. Together, these articles contribute to the evolving landscape of colorectal cancer research and the fight against this prevalent and impactful disease.
2021 Thematic Series: mRNA therapies and mRNA vaccines in cancer
Molecular Cancer is delighted to announce its new thematic series: mRNA therapies and mRNA vaccines in cancer
Click here to access all thematic series published to date in Molecular Cancer.
Featured Article: Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy
The CRISPR system is a revolutionary genome editing tool that has the potential to revolutionize the field of cancer research and therapy. The ability to precisely target and edit specific genetic mutations that drive the growth and spread of tumors has opened up new possibilities for the development of more effective and personalized cancer treatments.
In this review, the authors will discuss the different CRISPR-based strategies that have been proposed for cancer therapy, including inactivating genes that drive tumor growth, enhancing the immune response to cancer cells, repairing genetic mutations that cause cancer, and delivering cancer-killing molecules directly to tumor cells.
CAHON: Stop hate crimes and racism
The Chinese American Hematologist and Oncologist Network (CAHON) has published an important and timely Editorial in the Journal of Hematology & Oncology. Molecular Cancer is proud to stand with them in denouncing in the strongest terms all forms of discrimination and crimes against any racial/ethnic group, including Asian Americans and Pacific Islanders, and to call on our readers to pursue racial equality and tolerance in the USA and beyond.
Recognising Editorial Excellence
Molecular Cancer is a top rated Springer Nature journal. Prof. Christophe Nicot and the editorial team performed in the top percentile of journals based on data collected from the Journal Author Satisfaction Survey. We are recognising extraordinary editors for their commitment and passion to their journals. Read more about editorial excellence here.
What is trending?
Click here to see which articles published in Microbiome have been shared the most in 2021.
Springer Nature Oncology Portfolio
Discover the range of academic oncology titles at Springer Nature here.
Pre-submissions enquiries
The Editor-in-Chief does not accept pre-submission enquiries directed to his email address. Please contact journalsubmissions@springernature.com
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 27.7
5-year Journal Impact Factor: 31.3
Source Normalized Impact per Paper (SNIP): 4.737
SCImago Journal Rank (SJR): 8.222Speed 2024
Submission to first editorial decision (median days): 3
Submission to acceptance (median days): 86Usage 2024
Downloads: 4,693,166
Altmetric mentions: 1,438